SARS-CoV-2 infection in singleton pregnant women increases antiphospholipid antibody prevalence and placental dysfunction risk.
This prospective, observational cohort study evaluated singleton pregnant women without pre-existing pregnancy complications who tested positive for SARS-CoV-2 infection. Conducted at the Department of Obstetrics, Peking University People's Hospital, the study monitored patients from the time of infection through standard prenatal care protocols. Serum samples were collected 2–4 weeks post-infection to assess antibody status.
The primary outcome measured the prevalence of antiphospholipid antibodies (aPLs) and their impact on maternal-fetal outcomes. Secondary outcomes included positivity for lupus anticoagulant (LAC), anti-β2-glycoprotein I (aβ2GPI), anticardiolipin antibodies, and placental dysfunction complications. The overall prevalence of aPLs was 18.75% among the cohort.
Prevalence varied significantly by gestational stage, rising from 5.88% in the first trimester to 16.00% in the second and 26.31% in the third trimester. All positive cases exhibited single-antibody positivity, specifically for either aβ2GPI or LAC; no instances of multiple antibody co-positivity were observed. Positivity for aPLs, particularly LAC, was identified as an independent risk factor for placental dysfunction-related complications.
No adverse events, serious adverse events, discontinuations, or specific tolerability issues were reported in the provided data. The study notes that aPL positivity is an independent risk factor for complications related to placental dysfunction. While the study design is observational, the association between infection timing, antibody development, and placental dysfunction risk is clear. Clinicians should consider enhanced monitoring for placental dysfunction, vigilant surveillance of infection status and coagulation function, and appropriate obstetric management for infected women, especially those in the third trimester.